Submitted by Pater Tenebrarum via Acting-Man.com,A Look at the Broader Market’s InternalsWe have previously discussed the stock market’s deteriorating internals, and in light of recent market weakness want to take a brief look at the broader market in the form if the NYSE Index (NYA). First it has to be noted that a majority of the stocks in the NYA […]
A Look at the Broader Market’s InternalsWe have previously discussed the stock market’s deteriorating internals, and in light of recent market weakness want to take a brief look at the broader market in the form if the NYSE Index (NYA). First it has to be noted that a majority of the stocks in the NYA are already in bearish trends. […]
Investors haven’t been this cautious on the US stock market since 2007. According to Bank of America Merrill Lynch’s latest global fund manager survey, overall exposure to the US stock market moved to a 14% net underweight position. This marked the sixth-straight month that fund managers were net underweight the US stock market, the longest stretch since 2007 in the run-up to the financial […]
Online accounts now comprise 27% of total stock market accounts from a mere 6% share in 2009Rappler.comPublished 12:30 AM, August 17, 2015Updated 12:55 PM, Aug 17, 2015YOUNGER CROWD. Along with with the trend towards online use, the PSE survey also found that the average investor age is getting younger with just over half of all stock market accounts held by […]
Below is just a snapshot of the Full Report
(login required) Not a member yet? Join Now.
This report is provided free each week by McAlinden Research Partners to members of Hedge Connection.
Big Pharma Refills its Blockbuster Pipeline While the Generics Consolidate
MCALINDEN RESEARCH PARTNERS | DIBS
This Week’s Issue Cluster: Pharma
Generic drugmakers get on the megamerger bandwagon
New blockbuster branded drugs are coming down the pike, including Alzheimer’s, malaria, and cholesterol.
By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]
China’s stock markets cratered again today, despite the government’s stimulus efforts. The Shanghai Composite Index fell by 8.5% and the Shenzhen A-shares index lost 7% of its value.Over the past 10 years, today’s drop was the second-worst on record:The fall comes after the government reported a 0.3% drop in industrial profits in June, a sign that China’s economy may be […]
It’s old hat that biotech ETFs are beating the stock market. But three are new launches flying under the radar of many investors. BioShares Biotechnology Products (NASDAQ:BBP) holds stocks such as Celgene (NASDAQ:CELG) and Anacor Pharmaceuticals (NASDAQ:ANAC) that have shone of late. Two others focus on businesses in the clinical trial stage.http://news.investors.com/071615-762046-small-new-biotechnology-etfs-are-outperforming-peers.htm?ven=yahoocp&src=aurlled&ven=yahoo
View original –
Is Your Biotech ETF Keeping Up With 3 […]
The sheer size and importance of China’s equity markets cannot be overstated. Second in size only to the New York Stock Exchange, the combined value of the Asian country’s stock markets is $14 trillion and change. Or at least it was, before they fell 30 percent, wiping away nearly $2 trillion in value. To put this in perspective, the gross […]
Stock market investors in eastern China’s Zhejiang province. Photograph: AP
What goes up, can also come down, as the old adage and the modern-day investor warning go. And that is precisely what the tens of millions of people who hold shares in China have been discovering.Chinese stocks had doubled between last November and mid-June, to the delight of a fast-growing army […]